failed to reach significancep =0.09
23 From year 3 to year 5, there was a 56% relative reduction in relapse rate, but this failed to reach significance ( p =0.09). 23 In phase II and III studies, adverse events (AE) were reported in 96−100% of patients treated with Alemtuzumab 12 mg. 24 During the core studies, 2 deaths occurred in CAMMS223 (cardiovascular disease and idiopathic thrombocytopenic purpura (ITP)), one in CARE-MS I (automobile accident), and 2 in CARE-MS II (automobile accident and aspiration pneumonia following brainstem relapse).